For Immediate Release
Chicago, IL – October 27, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (
PFE Quick Quote PFE - Free Report) , Merck & Co., Inc. ( MRK Quick Quote MRK - Free Report) , Bristol-Myers Squibb Company ( BMY Quick Quote BMY - Free Report) and Amgen Inc. ( AMGN Quick Quote AMGN - Free Report) . Here are highlights from Monday’s Analyst Blog: Will Pfizer's ( PFE Quick Quote PFE - Free Report) Oncology Drugs Drive Q3 Earnings? Pfizer’s Biopharmaceuticals Group, which comprises six business units — Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine — is expected to have been the company’s key top-line driver in the third quarter.
Within the Biopharma group, oncology sales are likely to have risen in the third quarter, driven by higher sales of Ibrance, Inlyta, Xalkori and alliance revenues from Astellas for Xtandi.
Continued CDK class market share growth in the United States are likely to have driven Ibrance’s sales. However, pricing pressure in certain European markets is likely to have hurt its international sales.
Importantly, U.S. sales of Inlyta rose significantly in the past few quarters, gaining from FDA approvals in 2019 for the combination of Inlyta plus Pfizer’s Bavencio and Inlyta plus
Merck’s Keytruda in first-line treatment of advanced renal cell carcinoma patients. The trend is expected to have continued in the third quarter.
In non-oncology, sales of drugs like Xeljanz and alliance revenues from
Bristol-Myers for Eliquis are likely to have provided top-line support.
Pfizer’s stock has declined 2.6% this year so far, same as the
In addition, new brands such as Vyndaqel/Vyndamax, Braftovi, Mektovi and new oncology biosimilars (Trazimera, Zirabev and Ruxience) are expected to have brought in additional sales. However, patient starts for Vyndaqel are likely to have been impacted somewhat in the third quarter due to a slowdown in new diagnosis as fewer patients visited doctors amid the mobility restrictions.
Lower Prevnar sales in the United States due to slowdown in vaccination rates amid COVID-19-related mobility restrictions & limitations is also likely to have hurt the vaccine’s sales in the third quarter. However, it remains to be seen if sales trends have improved from the second-quarter levels. Meanwhile, increased adult uptake in international markets as people developed more vaccine awareness amid the COVID-19 pandemic might have benefited Prevenar 13 outside U.S. sales.
Meanwhile, sales of Chantix might have been significantly impacted due to lower demand from infrequent patient visits to doctors. However, sales trends might have improved from second-quarter levels.
The Zacks Consensus Estimate for sales of Ibrance (worldwide) and alliance revenues from Eliquis is $1.41 billion and $1.24 billion, respectively. The Zacks Consensus Estimate for Inlyta and Xeljanz’s sales is pegged at $216 million and $640 million, respectively.
Meanwhile, sales of important drug Enbrel in key European markets are likely to have declined due to continued biosimilar competition. Pfizer has exclusive rights to
Amgen’s blockbuster RA drug, Enbrel, outside the United States and Canada.
The Zacks Consensus Estimate for sales of Enbrel and Prevnar is $342 million and $1.68 billion, respectively.
Meanwhile, Pfizer’s sterile injectables portfolio is likely to have benefited from increasing demand due to the COVID-19 pandemic. Pfizer believes its anti-infective medicines as well as other sterile injectable products have been utilized in the incubation and ongoing treatment of mechanically ventilated COVID-19 patients.
Overall, in the third quarter,
higher sales of the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
Pfizer currently has a Zacks Rank #3 (Hold). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.